Deprecated: Required parameter $cat_id follows optional parameter $type in /www/wwwroot/ebimall.com/systems/hong.php on line 2088

Deprecated: Required parameter $where follows optional parameter $tree_id in /www/wwwroot/ebimall.com/systems/hlb.php on line 3505
Xcessbio/CTEP, mGlu5 Antagonist-Xcessbio Biosciences Inc/25 mg solid/M60099-25s188bio精品生物—专注于实验室精品爆款的电商平台 - 蚂蚁淘旗下精选188款生物医学科研用品
您好,欢迎您进入188进口试剂采购网网站! 服务热线:4000-520-616
蚂蚁淘商城 | 现货促销 | 科研狗 | 生物在线
产品资料

Xcessbio/CTEP, mGlu5 Antagonist-Xcessbio Biosciences Inc/25 mg solid/M60099-25s

Details
Product Information
Molecular Weight:391.77
Formula:C19H13ClF3N3O
Purity:≥ 98%
CAS#:871362-31-1
Solubility:DMSO up to 100 mM
Chemical Name:2-chloro-4-((2,5-dimethyl-1-(4-(trifluoromethoxy)phenyl)-1H-imidazol-4-yl)ethynyl)pyridine
Storage:Powder:4oC 1 year. DMSO:4oC3 month;-20oC 1 year.

Details

Biological Activity:

CTEP is a highly potent, selective and orally bioavailable allosteric antagonist of mGlu5 receptor with an IC50of 2.2 nM. It shows >1000-fold selectivity against 103 targets, including all known mGlu receptors. CTEP can penetrate the brain with a brain/plasma ratio of 2.6. CTEP is active in the stress-induced hyperthermia procedure in mice and the Vogel conflict drinking test in rats with minimal effective doses of 0.1 and 0.3 mg/kg, respectively, reflecting a 30- to 100-fold higher in vivo potency compared with 2-methyl-6-(phenylethynyl)pyridine (MPEP) and fenobam. CTEP is the first reported mGlu5 inhibitor with both long half-life of approximately 18 h and high oral bioavailability allowing chronic treatment with continuous receptor blockade with one dose every 48 h in adult and newborn animals. Acute CTEP treatment corrects elevated hippocampal long-term depression, protein synthesis, and audiogenic seizures. Chronic treatment that inhibits mGlu5 within a receptor occupancy range of 81% ± 4% rescues cognitive deficits, auditory hypersensitivity, aberrant dendritic spine density, overactive ERK and mTOR signaling, and partially corrects macroorchidism. By enabling long-term treatment through a wide age range, CTEP allows the exploration of the full therapeutic potential of mGlu5 inhibitors for indications requiring chronic receptor inhibition.

How to Use:

  • In vitro: CTEP was used at 0.03-0.1 µM final concentration in vitro and in cellular assays.
  • In vivo:CTEP was orally dosed to mice at single 0.1-1.0 mg/kg, or with a dose of 2 mg/kg orally every 48 h for 2 months. CTEP was orally dose at 2 mg/kg BID achieves uninterrupted mGlu5 occupancy per 48 hours in mice.

Reference:

  • 1. Lindemann L, et al. CTEP: a novel, potent, long-acting, and orally bioavailable metabotropic glutamate receptor 5 inhibitor. (2011) J Pharmacol Exp Ther. 339(2):474-86.
  • 2. Michalon A, et al. Chronic pharmacological mGlu5 inhibition corrects fragile X in adult mice. (2012) Neuron. 74(1):49-56.
  • Product Specification:
  • CTEP_spec.pdf
  • Product MSDS:
  • CTEP_MSDS.pdf
Products are for research use only. Not for human use.

新闻动态
行业前沿
技术文章
最新产品